Becton Dickinson
BDX
$159.93
+3.26%
Becton, Dickinson and Co. (BDX) is a global medical technology company that manufactures and sells a broad portfolio of medical supplies, devices, and diagnostic systems across four business units: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. As a diversified healthcare stalwart with over 60% of revenue from the U.S., BDX holds a strong competitive position in core markets like infusion pumps, medication dispensing, and prefillable syringes. The current investor narrative centers on a turnaround story, as the company navigates a recent revenue decline and a net loss in its fiscal Q2 2026, while simultaneously raising its full-year profit outlook and appointing a new CFO, signaling management's confidence in operational improvements.…
BDX
Becton Dickinson
$159.93
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating: Hold. BDX is a turnaround story with deep value characteristics but significant operational headwinds. The consensus analyst rating is Buy with an average target of $179.36, implying 15.8% upside, but the recent net loss and revenue decline warrant caution.
Supporting Evidence: The primary valuation metric, P/S, is 1.93x, near the bottom of its historical range of 7-12x, suggesting a deep value discount. Revenue growth is negative at -10.6% YoY, and profitability has deteriorated sharply with a net loss of -$311 million in Q2. However, free cash flow remains strong at $3.1B TTM, and the forward P/E of 11.5x (based on estimated EPS of $16.43) is attractive if earnings materialize. The implied upside to the average analyst target is 15.8%, but the low target of $161 offers only 4% upside.
Risks & Conditions: The biggest risks are continued revenue decline and margin compression. This Hold would upgrade to Buy if revenue growth turns positive and operating margins recover above 10%, or if the stock pulls back to the 52-week low of $127.59, offering a larger margin of safety. It would downgrade to Sell if revenue declines accelerate beyond -15% or if free cash flow turns negative. Overall, BDX appears undervalued relative to its historical multiples but fairly valued given the current earnings distress.
Sign up to view all
BDX 12-Month Price Forecast
BDX is a high-risk, high-reward turnaround play. The stock is deeply undervalued on a historical basis, but the fundamental deterioration (net loss, revenue decline) justifies the discount. The base case of stabilization and modest recovery is most likely, but the bear case of further decline is equally plausible given the negative momentum. The neutral stance reflects the balanced risk/reward: the stock could rally 15% if the turnaround succeeds, or fall 18% if it fails. Key catalysts to watch are the next earnings report and any updates on cost-cutting initiatives. An upgrade to bullish would require positive revenue growth and margin expansion; a downgrade to bearish would follow a further deterioration in earnings.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $179.36 and implied upside of +12.2% versus the current price.
Average Target
$179.36
0 analysts
Implied Upside
+12.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$161 - $225
Analyst target range
BDX is covered by 11 analysts, with a consensus recommendation of 'Buy' (mean rating of 2.08 on a 1-5 scale, where 1 is Strong Buy). The average target price is $179.36, implying approximately 15.8% upside from the current price of $154.88. The distribution shows a bullish lean, with firms like Evercore ISI (Outperform), Barclays (Overweight), and Citigroup (Buy) maintaining positive ratings, while TD Cowen and Piper Sandler rate it Hold/Neutral. The target price range spans from a low of $161.00 to a high of $225.00. The high target of $225.00 assumes a successful turnaround with margin expansion and revenue recovery, potentially driven by new product launches and cost efficiencies. The low target of $161.00 prices in continued headwinds from revenue decline and margin compression. The spread between low and high ($64) is moderate, indicating some uncertainty but not extreme divergence. Recent ratings have been stable, with no downgrades in the past few months, suggesting analysts are cautiously optimistic about the company's outlook following the Q2 beat and raised guidance.
Bulls vs Bears: BDX Investment Factors
BDX presents a classic turnaround debate. On the bull side, the stock is cheap historically (P/S 1.93x), analysts see 15.8% upside, and management just raised guidance and appointed a new CFO. Free cash flow remains strong at $3.1B TTM. On the bear side, the company is in a sustained downtrend, revenue is shrinking 10.6%, and it posted a net loss of $311M in Q2. The single most important tension is whether the Q2 loss is a one-time blip or the start of a structural decline. If revenue stabilizes and margins recover, the low valuation could drive significant upside. If the revenue decline accelerates, further downside toward the 52-week low of $127.59 is possible. Currently, the bear case has stronger evidence given the negative earnings trend, but the valuation discount and analyst optimism provide a counterbalance.
Bullish
- Analyst consensus Buy with 15.8% upside: 11 analysts rate BDX a Buy (mean 2.08/5), with an average target of $179.36, implying 15.8% upside from $154.88. The high target of $225 suggests significant potential if the turnaround succeeds.
- Raised profit outlook and new CFO: On May 7, 2026, BDX hiked its full-year profit outlook and named a new CFO, signaling management confidence in operational improvements. This positive catalyst helped the stock bounce 6.4% in the past month.
- Strong free cash flow generation: TTM free cash flow is $3.142 billion, yielding ~7.5% of market cap. This provides a cushion for debt service and reinvestment, even amid a net loss quarter.
- Low beta of 0.27 offers downside protection: With a beta of 0.27, BDX is significantly less volatile than the market. This appeals to risk-averse investors and limits losses during broad selloffs, though it also caps upside.
Bearish
- Revenue decline of 10.6% YoY: Q2 2026 revenue fell to $4.714 billion from $5.272 billion a year ago, a 10.6% drop. This broad-based decline raises doubts about the turnaround's effectiveness.
- Net loss of $311 million in Q2: BDX swung from net income of $308 million to a net loss of $311 million YoY, resulting in a negative net margin of -6.6%. Operating margin collapsed to 2.0% from 10.4%.
- Stock in sustained downtrend: BDX is down 13.1% over the past year vs. S&P 500 +20.9%, and -25.2% over 6 months. The price sits at 47% of its 52-week range, indicating persistent selling pressure.
- Negative EPS and no P/E visibility: TTM EPS is negative (-$1.11 in Q2), making the trailing P/E meaningless. Forward P/E of 11.5x relies on estimated EPS of $16.43, which may be at risk if losses continue.
BDX Technical Analysis
BDX is in a sustained downtrend, with the stock price declining 13.14% over the past year, significantly underperforming the S&P 500's 20.92% gain. The current price of $154.88 sits at approximately 47% of its 52-week range (low $127.59, high $187.35), indicating the stock is closer to its lows than highs, which could suggest a value opportunity but also reflects persistent selling pressure. The 1-year relative strength of -34.06% underscores the stock's pronounced weakness versus the broader market. Short-term momentum shows a mixed picture: the 1-month price change is +6.43%, a notable bounce from the 6-month decline of -25.22%, suggesting a potential short-term recovery. However, the 3-month change is a mere +0.04%, indicating that the recent uptick has barely recovered from the steep selloff earlier in the year. This divergence between the 1-month rally and the longer-term downtrend could signal a temporary pullback or the early stages of a trend reversal, but confirmation is needed. The 52-week low of $127.59 provides key support, while the 52-week high of $187.35 represents major resistance. A breakout above $187.35 would signal a strong reversal, while a breakdown below $127.59 could accelerate losses. BDX's beta of 0.27 indicates the stock is significantly less volatile than the market, meaning it tends to move less than the S&P 500, which may appeal to risk-averse investors but also implies limited upside participation in bull markets.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-10.3%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | +10.2% | +0.1% |
| 3m | +0.9% | +5.7% |
| 6m | -22.8% | +8.5% |
| 1y | -10.3% | +20.3% |
| ytd | -18.0% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
BDX's revenue trajectory has turned negative, with the most recent quarter (Q2 2026) reporting revenue of $4.714 billion, a 10.58% year-over-year decline. This follows a pattern of decelerating growth: Q1 2026 revenue was $5.252 billion (down from $5.168 billion in Q1 2025), and prior quarters showed more robust figures. The decline is broad-based, with Medical segment revenue of $2.4 billion and Life Sciences at $2.5 billion, both likely under pressure. The negative growth raises concerns about the company's near-term top-line momentum and the effectiveness of its turnaround strategy. Profitability has deteriorated sharply: BDX reported a net loss of $311 million in Q2 2026, compared to net income of $308 million in the same quarter last year, resulting in a negative net margin of -6.6%. Gross margin improved slightly to 45.69% from 42.81% a year ago, but operating margin collapsed to 1.99% from 10.36%, driven by higher operating expenses. The company swung from positive EPS of $1.07 in Q2 2025 to a loss of $1.11 per share, highlighting significant earnings pressure. BDX maintains a manageable balance sheet with a debt-to-equity ratio of 0.76 and a current ratio of 1.11, indicating adequate liquidity. Free cash flow generation remains solid at $546 million in Q2 2026, though down from $1.002 billion in Q4 2025. The company's ROE of 6.61% is modest, and the FCF yield of approximately 7.5% (based on market cap of $42.2 billion) suggests reasonable cash generation relative to valuation, but the negative net income raises questions about earnings quality.
Quarterly Revenue
$4.7B
2026-03
Revenue YoY Growth
-10.6%
YoY Comparison
Gross Margin
45.7%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given that BDX reported negative net income in the trailing twelve months (TTM net income of -$311 million for Q2 2026), the P/E ratio is not meaningful. Therefore, we lead with the price-to-sales (P/S) ratio. The trailing P/S ratio is 1.93x, while the forward P/S (based on estimated revenue of $21.875 billion) is approximately 1.93x as well, implying stable sales expectations. The gap between trailing and forward is negligible, suggesting the market does not anticipate significant revenue growth or contraction in the near term. Compared to the industry average (not provided, but typically for medical instruments & supplies, P/S averages around 2-3x), BDX's P/S of 1.93x appears to be at a discount, potentially reflecting the recent revenue decline and earnings loss. The EV/Sales multiple of 2.66x further supports a moderate valuation. Historically, BDX's P/S ratio has ranged from about 7x to 12x over the past few years, as seen in historical ratios data (e.g., 11.6x in Q4 2021). The current P/S of 1.93x is near the bottom of its historical range, indicating that the market is pricing in significant pessimism. This could represent a value opportunity if the company's fundamentals stabilize, but it also suggests that the market has already discounted much of the bad news.
PE
25.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BDX's most immediate financial risk is its negative net income of -$311 million in Q2 2026, which swung from a $308 million profit a year ago. Operating margin collapsed to 2.0% from 10.4%, driven by higher operating expenses. The debt-to-equity ratio of 0.76 is manageable, but interest expense of $149 million in Q2 consumes a significant portion of operating income ($94 million). Revenue concentration is moderate, with 60% from the U.S., but the 10.6% YoY decline suggests broad-based weakness. Free cash flow of $546 million in Q2 is down from $1.0B in Q4 2025, indicating potential cash flow pressure if the trend continues.
Market & Competitive Risks: BDX trades at a P/S of 1.93x, near historical lows, but this discount reflects the market's pricing of the revenue decline and earnings loss. The stock's beta of 0.27 means it is less correlated with the market, but its relative strength of -34% over the past year shows severe underperformance. Competitive risks include pricing pressure in medical supplies and potential disruption from new entrants in infusion pumps and medication dispensing. Regulatory headwinds in healthcare could also impact margins. The recent news of a raised profit outlook may help sentiment, but the stock remains in a downtrend.
Worst-Case Scenario: If the revenue decline accelerates and margins fail to recover, BDX could test its 52-week low of $127.59, representing a 17.6% downside from the current price of $154.88. In a severe recession or company-specific crisis, the stock could fall further, potentially to the analyst low target of $161 (which is above current price, but note the low target is $161, implying only 4% upside, so a realistic worst case could be below that). Historically, the max drawdown is -33%, which from current levels would imply a price of ~$103.77. An investor could lose up to 33% in an adverse scenario.
FAQ
The key risks are: 1) Financial risk: continued revenue decline (-10.6% YoY) and net losses (-$311 million in Q2) could erode shareholder value. 2) Competitive risk: pricing pressure in medical supplies and potential disruption in core markets like infusion pumps. 3) Macro risk: with a beta of 0.27, BDX is less correlated to the market, but a recession could further pressure healthcare spending. 4) Company-specific risk: the new CFO and raised guidance may not materialize, leading to disappointment. The most severe risk is a dividend cut if free cash flow deteriorates further.
The 12-month forecast is mixed. The bull case (25% probability) sees the stock reaching $179-$225, driven by a successful turnaround and margin recovery. The base case (50% probability) targets $161-$179, assuming revenue decline moderates and margins stabilize. The bear case (25% probability) sees the stock falling to $127-$161 if the decline accelerates. The most likely scenario is the base case, with the stock trading near the average analyst target of $179.36, implying 15.8% upside. However, the negative earnings trend makes the forecast highly uncertain.
BDX appears undervalued relative to its own history, with a trailing P/S ratio of 1.93x compared to historical ranges of 7-12x. However, this discount reflects the current earnings distress and revenue decline. The forward P/E of 11.5x (based on estimated EPS of $16.43) is attractive if earnings materialize, but the trailing P/E is not meaningful due to negative net income. Compared to the medical instruments industry average P/S of 2-3x, BDX trades at a discount. The market is pricing in significant pessimism, which could be an opportunity if the turnaround succeeds, but also implies that the stock is fairly valued given the current fundamentals.
BDX is a speculative buy for investors with a high risk tolerance and a long-term horizon. The stock offers a 15.8% upside to the average analyst target of $179.36, and the P/S ratio of 1.93x is near historical lows, suggesting deep value. However, the company reported a net loss of $311 million in Q2 2026 and a 10.6% revenue decline, which are significant headwinds. The biggest downside risk is a further decline to the 52-week low of $127.59, representing a 17.6% loss. For value investors who believe the turnaround will succeed, BDX could be a good buy at current levels. For conservative investors, it may be better to wait for evidence of revenue stabilization.
BDX is more suitable for long-term investment (12-24 months) given its turnaround nature and low beta of 0.27, which limits short-term trading opportunities. The stock's 1-month bounce of 6.4% suggests short-term momentum, but the 6-month decline of -25.2% indicates a strong downtrend. The dividend yield of 2.84% provides some income, but the payout ratio of 71% is high and could be at risk. For long-term investors, the potential for multiple expansion from historically low P/S levels offers significant upside if the turnaround succeeds. Short-term traders may find limited volatility due to the low beta.